Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $72.6 million versus the consensus estimate of $65.02 million.

GUIDANCE:

Exact Sciences sees FY2017 revenue of $254-257 million, versus the consensus of $244.25 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.